By VETTAPHARMA reporter – Derek Roche: Glenmark Pharmaceuticals Inc., USA has announced the launch of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials in the United States. The product is bioequivalent and therapeutically equivalent to Vimpat® Injection, 200 mg/20 mL (10 mg/mL) of UCB, Inc. under NDA 022254.
According to IQVIA® sales data for the 12-month period ending April 2026, the U.S. Vimpat Injection market, including the branded product and all available therapeutic equivalents, generated approximately $15.2 million in annual sales.
Marc Kikuchi, President & Business Head, North America at Glenmark, said the launch reflects the company’s strategy to expand its differentiated U.S. product portfolio while strengthening its injectable medicines business. He added that the introduction of Lacosamide Injection supports Glenmark’s commitment to improving patient access to quality and affordable treatment options.
The launch further expands Glenmark’s U.S. generics portfolio and strengthens its presence in the injectable segment. The company noted that its Lacosamide Injection is approved only for the indications included in its approved labeling.
Glenmark Pharmaceuticals Limited operates 11 manufacturing facilities across four continents, supported by six research and development centers, and maintains a commercial presence in more than 80 countries worldwide.
Quick FAQs
1. What Is Lacosamide Injection USP?
Lacosamide Injection USP is a generic injectable medicine launched by Glenmark in the United States as a bioequivalent and therapeutically equivalent version of Vimpat® Injection.
2. What Happened?
Glenmark Pharmaceuticals Inc., USA announced the launch of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials in the U.S. market.
3. What Is the Product Approval Based On?
Glenmark’s product is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat® Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc. under NDA 022254.
4. What Is the Relevant Disease Condition?
The provided source identifies Lacosamide Injection USP as the generic equivalent of Vimpat® Injection but does not specify the approved indication(s) in the announcement.
5. What Are the Key Commercial Details?
The U.S. Vimpat Injection market generated approximately $15.2 million in annual sales during the 12 months ending April 2026, according to IQVIA® data.
6. Why Is This Important?
The launch expands Glenmark’s injectable product portfolio in the United States and may help improve patient access to affordable treatment options while increasing competition in the market.
